| Field | Specification |
|---|---|
| Target | |
| Alternative names | Glial fibrillary acidic protein; GFAP |
| UniProt # | |
| Host | |
| Clone | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E.coli-derived human GFAP recombinant protein (Position: Q93-M432). Human GFAP shares 94% amino acid (aa) sequence identity with both mouse and rat GFAP. |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
Clone 3F2 is a mouse monoclonal antibody that recognizes glial fibrillary acidic protein (gene GFAP) in human, mouse and rat samples and is validated for Western blot, IHC and ICC/IF. The predicted molecular weight is 49.9 kDa, and the supplier reports an observed band at about 50 kDa.
Glial fibrillary acidic protein (GFAP) is a type III intermediate filament protein expressed mainly in astrocytes. It is the classic marker for astrocytes and for reactive astrogliosis after injury or disease. Mutations in GFAP cause Alexander disease, and GFAP levels are studied as a marker of brain injury.
| Target | Glial fibrillary acidic protein (gene GFAP; UniProt P14136, human) |
|---|---|
| Clone | 3F2 |
| Host / Clonality / Isotype | Mouse / Monoclonal / Mouse IgG1 |
| Reactivity | Human, Mouse, Rat |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4; 0.05 mg NaN3 |
| Calculated MW | 49.9 kDa |
| Observed MW | 50 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.1–0.5 µg/mL (Mouse, Rat) |
|---|---|
| IHC (paraffin sections) | 0.5–1 µg/mL (Human, Mouse, Rat) |
| Immunocytochemistry / Immunofluorescence | 5 µg/mL (Rat) |
Samples with a confirmed band (WB): rat brain tissue, mouse brain tissue.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 50 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:10000, ECL detection.
Samples with confirmed staining (IHC): human glioma tissue, rat brain tissue, rat cerebral cortex tissue, rat hippocampus tissue, mouse hippocampus tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Samples with confirmed staining (ICC/IF): rat brain tissue.
Immunogen
Recombinant human GFAP fragment (Gln93–Met432), expressed in E. coli. Sequence identity with the mouse and rat orthologs: 94%.
Reactivity Notes
The supplier lists reactivity with human, mouse and rat. UniProt places glial fibrillary acidic protein in the cytoplasm. Tissue expression noted by UniProt (human): Expressed in cells lacking fibronectin. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
Xinjin Su et al. (2024) Chitosan-Modified Hydrogel Microsphere Encapsulating Zinc-Doped Bioactive Glasses for Spinal Cord Injury Repair by Suppressing Inflammation and Promoting Angiogenesis. Advanced Healthcare Materials. 10.1002/adhm.202402129
Xin Liu et al. (2012) Protective effects of cationic bovine serum albumin-conjugated PEGylated tanshinone IIA nanoparticles on cerebral ischemia. Biomaterials. 10.1016/j.biomaterials.2012.10.017
Gusthavo Rodrigues et al. (2021) Resistance Exercise and Whey Protein Supplementation Reduce Mechanical Allodynia and Spinal Microglia Activation After Acute Muscle Trauma in Rats. Frontiers in Pharmacology. 10.3389/fphar.2021.726423
Moraes Thamyris Reis et al. (2024) Spinal HMGB1 participates in the early stages of paclitaxel-induced neuropathic pain via microglial TLR4 and RAGE activation. Frontiers in Immunology. 10.3389/fimmu.2024.1303937
Chen Ling et al. (2016) Lentiviral Vector-Induced Overexpression of RGMa in the Hippocampus Suppresses Seizures and Mossy Fiber Sprouting. Molecular Neurobiology. 10.1007/s12035-016-9744-2
Yu Zhang et al. (2021) SerpinA3N attenuates ischemic stroke injury by reducing apoptosis and neuroinflammation. CNS Neuroscience & Therapeutics. 10.1111/cns.13776
Xiaowei Zhang et al. (2013) Human Astrocytic Cells Support Persistent Coxsackievirus B3 Infection. Journal of Virology. 10.1128/JVI.02090-13
Zhao Qi-Wen et al. (2017) NDGA-P21, a novel derivative of nordihydroguaiaretic acid, inhibits glioma cell proliferation and stemness. Laboratory Investigation. 10.1038/labinvest.2017.46
Yonghui Hou et al. (2025) Tauroursodeoxycholic acid regulates macrophage/monocyte distribution and improves spinal microenvironment to promote nerve regeneration through inhibiting NF-κB signaling pathway in spinal cord injury. Frontiers in Pharmacology. 10.3389/fphar.2025.1554945
Xingliang Dai et al. (2016) 3D bioprinted glioma stem cells for brain tumor model and applications of drug susceptibility. Biofabrication. 10.1088/1758-5090/8/4/045005
